CMND Archives - BioTuesdays

Developments

NeuroThera expands IP portfolio through collaboration with Clearmind

NeuroThera Labs (TSXV: NTLX) has highlighted the expansion of the U.S. intellectual property (IP) portfolio through its ongoing collaboration with Clearmind Medicine (NASDAQ: CMND). As part of the collaboration, three U...

September 24, 2026

Developments

First AUD patients enrolled in Clearmind’s psychedelic-based treatment trial

Clearmind Medicine (NASDAQ: CMND) has announced the enrollment of the first patients with alcohol use disorder (AUD) in its ongoing clinical trial evaluating CMND-100, the company’s proprietary psychedelic-based...

September 11, 2026

Developments

Clearmind announces positive results for intranasal MEAI

Clearmind Medical (NASDAQ: CMND; FSE: CWY0) has announced positive permeation study results from its ongoing intranasal MEAI development program. According to Clearmind, early-stage studies of its intranasal MEAI...

August 11, 2026

Developments

USPTO grants Clearmind patent for binge behavior regulators

Clearmind Medicine (NASDAQ: CMND) has been granted a U.S. patent titled “BINGE BEHAVIOR REGULATORS”, by the United States Patent and Trademark Office (USPTO). The patent, which refers to Clearmind’s molecule MEAI (5...

June 19, 2026

Developments

Clearmind reports positive topline results from CMND-100 trial in AUD

Clearmind Medicine (NASDAQ: CMND) has announced that CMND-100, the company’s proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of alcohol use disorder (AUD), has met the primary endpoint in...

April 27, 2026

Developments

Clearmind advances recruitment for third cohort of CMND-100 trial at leading sites

Clearmind Medicine (NASDAQ: CMND) has announced the continuation of participant enrollment for the third cohort of its ongoing FDA-approved Phase 1/2a trial evaluating CMND-100, its proprietary non-hallucinogenic MEAI...

March 11, 2026

Developments

Clearmind achieves 100% treatment success in second cohort of CMND-100 trial in AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100—the...

January 14, 2026

Developments

Clearmind’s DSMB recommends continuation of trial for CMND-100 in AUD; patient enrollment at TASMC kicks off

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that its independent Data and Safety Monitoring Board (DSMB) has completed a scheduled interim review of its ongoing FDA-approved multinational Phase I/IIa...

November 25, 2025

Developments

Clearmind expands clinical trial for AUD to Hadassah Medical Center

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing, FDA-regulated Phase 1/2a clinical trial evaluating...

November 13, 2025

Executive Moves

Mary-Elizabeth Gifford joins Clearmind as Chief of Global Impact

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the appointment of Mary-Elizabeth Gifford as chief of global impact. Prior to joining Clearmind, Gifford served as chief of global impact at Psyence BioMed, a...

October 27, 2025

Tag - CMND

NeuroThera expands IP portfolio through collaboration with Clearmind

First AUD patients enrolled in Clearmind’s psychedelic-based treatment trial

Clearmind announces positive results for intranasal MEAI

USPTO grants Clearmind patent for binge behavior regulators

Clearmind reports positive topline results from CMND-100 trial in AUD

Clearmind advances recruitment for third cohort of CMND-100 trial at leading sites

Clearmind achieves 100% treatment success in second cohort of CMND-100 trial in AUD

Clearmind’s DSMB recommends continuation of trial for CMND-100 in AUD; patient enrollment at TASMC kicks off

Clearmind expands clinical trial for AUD to Hadassah Medical Center

Mary-Elizabeth Gifford joins Clearmind as Chief of Global Impact

Subscribe